Addex Therapeutics Files 6-K with Press Release
Ticker: ADXN · Form: 6-K · Filed: Jul 22, 2024 · CIK: 1574232
Sentiment: neutral
Topics: regulatory-filing, press-release, registration-statement
TL;DR
Addex Therapeutics filed a 6-K on 7/22/24, including a press release and referencing existing registration statements.
AI Summary
On July 22, 2024, Addex Therapeutics Ltd. announced the issuance of a press release. This press release is incorporated by reference into their Form 6-K filing with the SEC. The filing also references registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration Nos. 333-255124 and 333-27).
Why It Matters
This filing indicates ongoing corporate communications and regulatory compliance for Addex Therapeutics, potentially related to its ongoing development or financing activities.
Risk Assessment
Risk Level: low — The filing is a routine report of a foreign private issuer and does not contain new material financial information or significant corporate events.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- July 22, 2024 (date) — Date of press release and filing
- 333-255089 (registration_number) — Form F-3 registration number
- 333-255124 (registration_number) — Form S-8 registration number
- 333-27 (registration_number) — Form S-8 registration number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the issuance of a press release by Addex Therapeutics Ltd. on July 22, 2024, and to incorporate it by reference into the filing.
What exhibits are included with this Form 6-K?
Exhibit 99.1, a press release dated July 22, 2024, is included and incorporated by reference.
Which registration statements are referenced in this filing?
The filing references registration statements on Form F-3 (Registration No. 333-255089) and Form S-8 (Registration Nos. 333-255124 and 333-27).
Is Addex Therapeutics required to file annual reports under Form 20-F or 40-F?
Yes, Addex Therapeutics indicates it files annual reports under cover of Form 20-F.
Where is Addex Therapeutics Ltd. headquartered?
Addex Therapeutics Ltd. is headquartered in Geneva, Switzerland, with its principal executive office at Chemin des Mines 9, CH-1202 Geneva.
Filing Stats: 272 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-07-22 06:05:04
Filing Documents
- f6k_072224.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-004045.txt ( ) — 15KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] On July 22, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. (c) Exhibit 99.1. Press release dated July 22, 2024 INCORPORATION BY REFERENCE Exhibits 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd (Registrant) Date: July 22, 2024 /s/ Tim Dyer Tim Dyer Chief Executive Officer EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated July 22, 2024